About Lupus Research Alliance and Lupus Therapeutics, Our Clinical Research Arm

Lupus Research Alliance

- The Lupus Research Alliance (LRA) is the world’s largest non-governmental private funder of lupus research, spanning the full spectrum of discovery including foundational, translational, and clinical trials.
- The LRA is an organization of partnerships, bringing together key players in the fight against lupus — grantees, scientific advisors, pharmaceutical industry partners, the U.S. government, and people with lupus.
- LRA-funded research has contributed to the identification or further validation of at least 15 different disease pathways in lupus and has enabled the discovery, validation, or testing of more than a dozen different therapies for lupus.
- With new tools and technologies advancing personalized medicine, LRA is driving research to understand how lupus works in each person – to develop cures and individual treatments and, one day, a cure. Many of our research and advocacy programs are drawing in diverse perspectives from underrepresented patient and scientific groups to the discovery process.
- The LRA has committed more than $220 million for lupus research programs and issued 540+ grants.
- Our strategic research priorities are focused on: 1) Defining human lupus heterogeneity by molecular pathology; 2) Enabling patient stratification based on active disease mechanisms; and 3) Facilitating global research collaborations.
- 100 percent of all donations to the LRA go directly to support lupus research programs. Our Board of Directors cover all administrative and fundraising costs to ensure all money goes towards research programs.

Lupus Therapeutics

- The LRA established Lupus Therapeutics (LT) in 2018 to advance lupus clinical research to provide people with lupus faster, more equitable access to safe and effective therapies.
- As the clinical research accelerator arm of the LRA, LT partners with biopharmaceutical companies, clinical investigators, and community organizations to improve the clinical research process.
- LT manages the Lupus Clinical Investigators Network (LuCIN), comprised of more than 200 experienced clinician-scientists focused on lupus research to help treat over 25,000 people with lupus at 57 academic medical centers across North America.
- LT spearheads several initiatives to overcome barriers to trial participation by integrating the voices of patient-peer advocates into the entire clinical research process and increasing enrollment rates among diverse communities. Programs include Project CHANGE (Community-based Health Action Network to Generate trial participation and Eliminate disparities) and the PALS program (Patient Advocates for Lupus Studies).
  - Project CHANGE is a Community Based Participatory Research (CBPR) initiative aimed at ensuring African Americans living with lupus, one of the communities at greatest risk for developing serious complications due to lupus, are significantly represented in lupus clinical research, empowered to make decisions about research, and receive the best possible care when choosing to participate.
  - PALS is a peer-to-peer education program designed to improve clinical trial awareness, enrollment and retention among people with lupus in clinical research, particularly among diverse populations.

Visit LupusResearch.org and LupusTherapeutics.org to learn how, together with the worldwide lupus community, we are speeding up drug development while driving aggressively toward a cure.